Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Papillary Craniopharyngiomas
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically proven papillary craniopharyngioma as documented by central pathology review with positive BRAF V600E mutation by IHC.

You may not be eligible for this study if the following are true:

  • 1) Prior treatment with BRAF or MEK inhibitors. 2) Evidence of active bleeding, bleeding diathesis, or hemoptysis (= ½ teaspoon of red blood) = 8 weeks prior to registration.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.